The Technology
By combining advanced synthetic biology and microbiome engineering, this technology harnesses genetically modified bacteria to both diagnose and treat gut inflammation, such as Crohn’s disease and ulcerative colitis. These engineered bacteria are designed to detect specific biomarkers of inflammation (e.g., blood markers like heme) and respond by producing therapeutic compounds, precisely at the site of inflammation.
The system employs novel designs, including single-input multiplex logic gates and quorum sensing mechanisms, enabling precise, controlled delivery of therapies directly to inflamed regions. Early validation in mouse models has shown promising alleviation of the inflammation along with improved health outcomes. Multiple patent applications protect the diagnostic and therapeutic applications of this technology, ensuring a robust foundation for further development.
Advantages
- Precision targeting by localized therapeutic delivery to inflamed regions, reducing systemic side effects.
- Dual-action system by combining diagnostic sensing with therapeutic response in one platform.
- Minimizes disruption to the gut microbiome, based on the natural microbiota.
- Proven efficacy.
Applications and Opportunities
- Effective treatment for Inflammatory Bowel Disease (IBD), including Crohn’s disease and ulcerative colitis.
- Customizable therapies based on patient-specific microbiota.
- Broad adaptability for microbiome-linked conditions, such as autoimmune diseases, metabolic disorders, and more.
- Potential diagnostic applications: real-time, non-invasive monitoring of gut inflammation using engineered bacterial sensors.
Business Development Contacts